Back to search
Schizophrenia(Acute)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia(Acute) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Schizophrenia(Acute) trials you may qualify forThis is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus…
This study will investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis. A…
The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect bloo…
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007…
The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible ci…
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophreni…
The goal of this pilot randomized controlled trial is to learn if adult patients with acute psychiatric conditions can receive hospital-level care at home. The…